Summary & Overview
CPT 81298: Full-Gene Sequencing for MSH6
CPT code 81298 designates full-gene sequencing of the MSH6 (mutS homolog 6) gene performed by the technical laboratory component. Nationally, comprehensive MSH6 sequencing is used in hereditary cancer evaluation and can influence diagnostic classification, cascade testing, and clinical management pathways. This code captures a specialized molecular diagnostic service with implications for oncology, genetics, and preventive care programs.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a national view of coverage and billing context across major commercial and government payers.
Readers will find: an explanation of the clinical purpose and laboratory context for CPT code 81298; typical sites of service and service type; common billing modifiers and administrative notes (listed separately); and an overview of what to expect when seeking coverage or submitting claims for full MSH6 gene sequencing. The content summarizes policy-relevant points and operational considerations for laboratory billing teams, clinicians ordering genetic testing, and reimbursement analysts. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 81298 describes a laboratory procedure in which the technical laboratory component performs sequencing and analysis of the entire gene sequence for the mutS homolog 6 (MSH6) gene. This test is a molecular genetics sequencing assay that evaluates the full coding sequence of the MSH6 gene to identify variants that may be associated with hereditary cancer syndromes.
-
Service type: Molecular genetic sequencing (full gene analysis)
-
Typical site of service: Clinical molecular laboratory or reference laboratory capable of high-throughput gene sequencing
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult referred by a gastroenterologist or genetic counselor for germline MSH6 sequencing because of personal or family history suggestive of Lynch syndrome (hereditary nonpolyposis colorectal cancer). Common scenarios include a patient with early-onset colorectal cancer, multiple colorectal adenomas, endometrial cancer diagnosed before age 50, or a strong family history of colorectal and endometrial cancers. The clinical workflow: a clinician orders germline testing for mismatch repair genes; the patient provides informed consent and a blood or saliva sample is collected at an outpatient phlebotomy or genetic testing collection site. The specimen is sent to a clinical molecular diagnostics laboratory. The laboratory performs DNA extraction, library preparation, and next‑generation sequencing (NGS) or Sanger sequencing of the entire MSH6 gene. The lab analyst interprets variants according to ACMG/AMP guidelines and issues a report indicating pathogenic, likely pathogenic, variant of uncertain significance, likely benign, or benign findings, with recommendations for cascade testing where applicable. Typical sites of service include outpatient hospital laboratory, independent diagnostic testing facility (IDTF), or reference molecular diagnostic laboratory that bill under the technical component of testing.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing for the professional (interpretation) component separate from the technical testing. |